Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2016

View Archived Issues

Novartis reviews key milestones of fourth quarter 2015

Optogenetic modulation of response by controlling Ca2+ flow into cells: NIR-activated immunotherapy

Research Council of Norway awards funding to Bionor and Nordic Nanovector

Corvus initiates phase I/Ib study of CPI-444 in advanced cancer

Companies investigate approaches to tackle Zika virus

Shionogi updates progress of third quarter of fiscal 2015

Targovax submits a study protocol for ONCOS-102 trial to the regulatory authorities in Spain

AbbVie updates pipeline progress of fourth quarter 2015

The Medicines Company completes divestiture of hemostasis portfolio to Mallinckrodt

Recurrent genetic alterations identified in low-grade neuroepithelial tumors

Ligand licenses use of OmniAb platform to Tizona Therapeutics

Endomorphin analogues show potent analgesia with low side-effect profile

Repurposing RXR agonist HX-630: Possible new treatment for Cushing's disease?

Abbott to acquire Alere

Ono Pharmaceutical recaps highlights of third quarter of fiscal 2015

Neurocrine initiates phase II study of valbenazine in pediatric patients with Tourette syndrome

LEO Pharma and arGEN-X select cell line for manufacture of antibody against skin inflammation

Trimesta shows no benefit in relapsing-remitting MS in women

Versartis reports results from extension study of somavaratan in children with GHD

FDA issues CRL regarding Telesta Therapeutics' MCNA

Tagrisso approved in E.U. for EGFR-mutant NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...